García-Figueroa RB, Araiza-Santibáñez J, Basurto-Kuba E, Bonifaz-Trujillo A

Language: Spanish
References: 44
Page: 455-460
PDF size: 89.24 Kb.

ABSTRACT

Background: Candida genus has various species. The incidence of C. glabrata has presented itself with more frequency over the past years with clinical importance. Methods: A case study was made to determine the frequency of C. glabrata in 468 patients who presented clinical symptomatology for vulvovaginal candidiasis and the in vitro response for fluconazole using two methods: diffusion in agar plates and microdilution in liquid medium [NCLSI (NCCLS) method]. Results: The frequency for this specie was 12.6%, almost double the frequency observed 10 years ago. The resistance of C. glabrata to fluconazole treatment was confirmed in this study, representing 68.2% resistance in all the stains on test plates and 51.2% on NCLSI method with a MIC of 16 μg/ml. Conclusions: The frequency of Candida glabrata has increased over the past years. It presents resistance to usual treatments, which promotes the persistency and recurrence of genital and systemic infections.

REFERENCES

5. Bodey GP. Candidiasis. Pathogenesis, diagnosis, and treatment. 2nd ed.New York: Raven Press; 1993; pp. 1-420.

6. Bonifaz A. Candidosis. Micología Médica Básica. Tercera edición. México: McGraw-Hill; 2009. pp. 301-329.

7. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 1991;91:86S-89S.

8. Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, et al. International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diag Microbiol Infect Dis 1999;35:19-25.

9. Harris AD, Castro J, Sheppard DC, Carmeli Y, Samori MH. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans. Clin Infect Dis 1999;29:236-238.

10. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996;9:499-511.

11. Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995;8:462-478.

12. Pfaller M, Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992;11:287-291.

13. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000;30:662-678.

14. Buitrón R, Romero R, Bonifaz A. Estudio de especies Candida no albicans y su relación con candidiasis vulvovaginal recurrente. Ginecol Obstet Mex 2002;70:431-436.

15. 11.Muriel MA, Vizcaíno MJ, Bilbao R, Herruzo N. Identificación de levaduras y sensibilidad in vitro a diversos antifúngicos. Enferm Infecc Microbiol Clin 2000;18:120-124.

16. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122-1128.

17. Saballs-Radresa P, Torres-Rodríguez JM, Salvadó M, Sales P, Gimeno- Bayón JL, Knobel H, et al. La candidemia en el síndrome de inmunodeficiencia adquirida. Estudio retrospectivo de nueve casos. Rev Iberoam Micol 2000;17:2-5.

18. Shin JH, Nolte FS, Holloway BP, Morrison CJ. Rapid identification of Candida species in blood cultures by a clinically useful PCR method. J Clin Microbiol 1997;35:1454-1459.

19. Peltroche-Llacsahuanga H, Schnitzler N, Lütticken R, Haase G. Rapid identification of Candida glabrata by using a dipstick to detect trehalosegenerated glucose. J Clin Microbiol 1999;37:202-205.

20. 16.Odds F. Candida and Candidosis. A Review and Bibliography. 2nd ed. London: Bailliere Tindall; 1988; pp. 7-15, 68-104.

21. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo, correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997;24: 235-247.

22. 18.Torres-Rodríguez JM, Madrenys N, Jiménez T, Saballs P. Concentraciones mínimas inhibitorias de levaduras a cinco antifúngicos utilizando un micrométodo de dilución estandarizado y el E-test. Rev Iberoam Micol 1997;14 :115-118.

23. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996;22:S89-S94.

24. Espinel-Ingrof A, Vázquez JA, Boikov D, Pfaller MA. Evaluation of DNAbased typing procedure for strain categorization of Candida spp. Diagn Microbiol Infect Dis 1999;33:231-239.

25. Berrouane YF, Hollis RJ, Pfaller MA. Strain variation among and antifungal susceptibilities of isolates of Candida krusei. J Clin Microbiol 1996;34:1856- 1858.

26. National Committee of Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard. NCCLS Document M27-A. Villanova: NCCLS; 1997. pp. 17:16.

27. Meis J, Petrou M, Bille J, Ellis D, Gibbs D. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Global antifungal surveillance group. Diagn Microbiol Infect Dis 2000;36:215-223.

28. Abbas J, Bodey GP, Hanna HA, et al. Candida krusei fungemia: an escalating serious infection in immunocompromised hosts. Arch Intern Med 2000;160:2659-2664.

29. Anaissie E, Hachem R, K-Tin-U C, Stephens LC, Bodey GP. Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: species differences in pathogenicity. Infect Immun 1993;61:1268-1271.